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Abstract
Introduction: Circulating tumor cells (CTCs) represent an independent predictor of outcome in patients with
metastatic breast cancer (MBC). We assessed the prognostic impact of CTCs according to different first-line
systemic treatments, and explored their potential predictive value in MBC patients.
Methods: We retrospectively evaluated 235 newly diagnosed MBC patients, treated at the University of Texas MD
Anderson Cancer Center. All patients had a baseline CTC assessment performed with CellSearch
®. Progression-free
survival and overall survival were compared with the log-rank test between groups, according to CTC count (< 5
vs. ≥ 5) and type of systemic therapy. We further explored the predictive value of baseline CTCs in patients
receiving different treatments.
Results: At a median follow-up of 18 months, the CTC count was confirmed to be a robust prognostic marker in
the overall population (median progression-free survival 12.0 and 7.0 months for patients with CTC < 5 and ≥ 5,
respectively; P < 0.001). Conversely, in patients with human epidermal growth factor receptor-2-overexpressed/
amplified tumors receiving trastuzumab or lapatinib, the baseline CTC count was not prognostic (median
progression-free survival 14.5 months for patients with CTC < 5 and 16.1 months for those with CTC ≥ 5; P =
0.947). Furthermore, in patients with human epidermal growth factor receptor-2 normal tumors, a baseline CTC
count ≥ 5 identified subjects who derived benefit from more aggressive treatments, including combination
chemotherapy and chemotherapy plus bevacizumab.
Conclusions: This analysis suggests that the prognostic information provided by CTC count may be useful in
patient stratifications and therapeutic selection, particularly in the group with positive CTCs, in which various
therapeutic choices may procure differential palliative benefit.
Introduction
The prognosis of patients with metastatic breast cancer
(MBC) has significantly improved over the last two dec-
ades [1]. Despite these advances, metastatic disease
remains largely incurable and the main goal of systemic
treatment is to prolong survival and maintain a high
quality of life [2]. Women with MBC represent a hetero-
geneous group of patients with different outcomes.
Classical factors such as age at diagnosis, hormone
receptor status, human epidermal growth factor recep-
tor-2 (HER-2) overexpression/amplification, and site of
metastases are currently used to stratify patients into
groups with different prognoses and to predict response
to systemic treatments [3]. Oncologists choose from a
wide variety of standard treatment options, including
endocrine therapies, chemotherapy-based regimens and
biologically targeted treatments, which may provide dif-
ferential palliative benefit [4]. The introduction of new
anti-tumor agents in clinical practice necessitates the
improvement of patient selection for personalized
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any medium, provided the original work is properly cited.treatment strategies. Indeed, the availability of early pre-
dictive markers of treatment response could prevent
exposure to ineffective therapies as well as to unneces-
sary treatment-related toxicity, and possibly reduce the
costs of treatment in patients with refractory disease [5].
Recently, the enumeration of circulating tumor cells
(CTCs) in the peripheral blood of cancer patients has
been associated with both disseminated disease and a
higher risk of cancer progression [6]. Several lines of
evidence confirm that the detection of CTCs represents
a new and reliable tool to predict the outcome of MBC
patients [7,8]. Furthermore, the enumeration of CTCs at
different time points during treatment has proven to be
a reliable surrogate marker of treatment response, and a
potential alternative for non-invasive therapy monitoring
[9-11]. Among several methods developed for CTC
detection, the CellSearch
® system (Veridex LLC, War-
ren, NJ, USA) is the only US Food and Drug Adminis-
tration-cleared test for CTC enumeration in clinical
practice [12]. Nevertheless, the availability of improved
and standardized techniques for detection and molecular
analysis of CTCs has allowed researchers to better
define the unique phenotypic characteristics of these
cells and their putative roles in cancer dissemination
[13]. As a predictor of disease progression and precur-
sors of metastases, CTCs provide an ideal model for the
development of new targeted treatments. Indeed, the
unique nature of these cells, which can be genetically
different from the primary tumor, is a peculiar feature
of tumor biology that should be considered when select-
ing targeted therapies [14-16].
Despite their potential therapeutic benefit, CTCs have
been studied mainly as a prognostic marker, while their
value as a predictive factor has remained largely unclear.
The objective of our retrospective study was to assess the
prognostic value of baseline CTCs in patients receiving
different first-line systemic treatments for MBC, and to
determine the possible predictive value of this marker.
Materials and methods
Study design
We retrospectively evaluated a population of 517 conse-
cutive MBC patients treated at The University of Texas
MD Anderson Cancer Center, Houston, TX, USA. Each
patient had a standard CTC assessment before starting
systemic treatment. From all the patients examined, we
selected 235 women who received first-line systemic
therapy between September 2004 and November 2009.
The principal eligibility criteria for this study included
patients with newly diagnosed metastatic disease, CTC
evaluation performed as standard of care within 30 days
before starting any systemic treatment, and availability of
treatment and follow-up information. Tumor response
was evaluated according to the response evaluation
criteria in solid tumors [17,18]. The histological type,
tumor grade, hormone receptor status, and HER-2/neu
status were evaluated on the primary tumor or, when
available, on metastatic disease. The HER-2/neu status
was determined using immunohistochemistry and/or
fluorescent in situ hybridization techniques. Patients’
treatments were selected according to the National Com-
prehensive Cancer Network and Institutional guidelines
[19]. The institutional review board at the University of
Texas MD Anderson Cancer Center approved the study
and granted a waiver of informed consent, considering
the retrospective nature of the study (DR10-0227).
Isolation and enumeration of circulating tumor cells
Blood samples (7.5 ml) were drawn into CellSave
® tubes
(Veridex LLC), which were maintained at room tempera-
ture and processed within 72 hours of collection. The
standardized CellSearch System
® (Veridex LLC) was
used for isolating and enumerating CTCs, as reported
previously [7,14]. CTCs were defined as nucleated
EpCAM-positive cells, lacking CD45 but expressing cyto-
plasmic cytokeratins 8, 18, and 19. All CTC evaluations
were performed by qualified and trained personnel.
Patients were categorized according to baseline CTC
counts as having favorable (< 5 CTCs/7.5 ml blood) or
unfavorable (≥ 5 CTCs/7.5 ml blood) outcome.
Statistical analysis
All clinical data were collected independently by two
physicians (MG and AG) from the MD Anderson elec-
tronic medical record (ClinicStation
®). Progression-free
survival (PFS) was calculated from the date of CTC eva-
luation to the date of clinical disease progression or
death; in the absence or either progression or death,
patients were censored at the date of the last follow-up.
Overall survival (OS) was defined as the time elapsed
between the date of CTC assessment and the date of
either death or last follow-up.
The Fisher’s exact test and the Pearson’s chi-square test
were used to determine significant differences in patient
characteristics according to baseline CTC count. The
prognostic effect of CTCs was explored in the overall
population and within different subgroups of patients
according to treatment received (endocrine treatment or
different regimens of chemotherapy). The PFS and OS
were estimated using the Kaplan-Meier product limit
method. The log-rank test was used to compare PFS and
OS between groups, according to the CTC count (< 5 vs.
≥ 5) and the type of systemic therapy. To confirm CTCs
as an independent prognostic factor, Cox proportional
hazard models for PFS and OS were fit, adjusting for hor-
mone receptor status (positive vs. negative), HER-2/neu
status (amplified/overexpressed vs. normal), number of
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(visceral vs. other).
The predictive value of CTCs was explored by evaluat-
ing the interaction between efficacy of different treat-
ments and baseline value of CTCs. The effect of
treatments was expressed as hazard ratios with 95% con-
fidence intervals (CIs), and a forest plot was generated
to display results. To evaluate the interaction between
treatment effect and CTC count, we quantified the het-
erogeneity between subgroups (CTCs < 5 and ≥ 5) with
the Higgins’ I
2 index [20]. All statistical analyses, per-
formed using the PASW Statistical Analysis for Social
Sciences statistics 18 software (SPSS Inc., Chicago, IL,
USA), were two-sided and P < 0.05 was considered
statistically significant.
Results
Patient characteristics
Demographic and disease characteristics of the 235
patients evaluated in this analysis are reported in Table 1.
The median age of patients was 53 years (range 28 to 82
years). One hundred and fifty-one patients had hormone
receptor-positive disease. Visceral metastases were
detected in approximately 60% of patients. The baseline
value of CTCs per 7.5 ml blood was < 5 in 141 (60%) and
≥ 5 in 94 (40%) patients. A higher percentage of patients
with ≥ 5C T C sa tb a s e l i n eh a dt h r e eo rm o r em e t a s t a t i c
sites of disease at baseline (45.7% vs. 29.8%, P =0 . 0 1 1 ) .
No statistically significant difference in metastatic site
(visceral vs. other) or in the distribution of immunohisto-
chemistry-defined molecular subtypes was observed
according to CTC value.
All patients received first-line systemic therapy for
newly diagnosed MBC (Table 2). Forty-seven patients
(20%) received endocrine therapy, 109 (46.4%) were
treated with chemotherapy alone, 39 (16.6%) received
bevacizumab associated with taxane-based chemother-
apy, and 40 patients (17%) with HER-2-overexpressed/
amplified disease received chemotherapy combined with
a HER-2 targeting drug, including trastuzumab and
lapatinib.
Prognostic value of circulating tumor cells in the overall
population
The median follow-up for all patients and for patients
still alive was 17 months and 18 months, respectively.
At the time of the analysis, 87 patients (37%) had died
and 179 patients (76%) experienced disease progression.
We found a remarkable correlation between the baseline
value of CTCs and the outcome of all patients. The
median PFS was 12.0 months (95% CI = 9.6 to 14.3) for
patients with CTCs < 5 and 7.0 months (95% CI = 5.8
to 8.1) for those with CTCs ≥ 5( l o g - r a n kP < 0.001).
The median OS was 40.1 months (95% CI = 34.9 to
45.4) for women with a low CTC and 21.9 months (95%
CI = 15.5 to 28.3) for those with CTCs ≥ 5( l o g - r a n k
P < 0.001; Figure 1).
Furthermore, in multivariate analysis the baseline
count of CTCs was confirmed to be an independent
predictor of PFS and OS, regardless of hormone recep-
tor status, HER-2 status, location or number of meta-
static sites (Table 3).
Effect of different treatments on the circulating tumor
cell detection rate
We analyzed the effect of different systemic treatments
on CTC count. For 144 patients (61%), a follow-up eva-
luation of CTCs was available. The median time
between baseline and follow-up CTC evaluations was 10
weeks (15% of the patients had a follow-up count within
week 6 from baseline, 53% from week 6 to week 12,
22% from week 13 to week 19, and 10% from week 20
Table 1 Patient characteristics stratified by baseline circulating tumor cell value
Variable Overall CTC < 5 CTC ≥ 5 P value
All patients 235 (100) 141 (60) 94 (40) -
Age (years) 53 (23 to 82) 53 (28 to 82) 53 (23 to 81) 0.451
Follow-up (months) 18 (1 to 65) 20 (1 to 65) 18 (3 to 61) -
HR
+/HER-2 normal 130 (55.3) 74 (52.5) 56 (59.6) 0.349
HR
+/HER-2 overexpressed/amplified 21 (8.9) 15 (10.6) 6 (6.4) 0.352
HR
-/HER-2 overexpressed/amplified 22 (9.4) 13 (9.2) 9 (9.6) 1.0
Triple receptor negative 62 (26.4) 39 (27.7) 23 (24.4) 0.651
Visceral metastases 140 (59.6) 80 (56.7) 60 (63.8) 0.342
Number of metastatic sites
1 85 (36.2) 61 (43.3) 24 (25.5) 0.011*
2 65 (27.6) 38 (26.9) 27 (28.8)
≥ 3 85 (36.2) 42 (29.8) 43 (45.7)
Data presented as n (%) or median (range). CTC, circulating tumor cell; HER-2, human epidermal growth factor receptor-2; HR
+, estrogen receptor-positive and/or
progesterone receptor-positive; HR
-, both estrogen receptor-negative and progesterone receptor-negative. * Statistical significant value.
Giuliano et al. Breast Cancer Research 2011, 13:R67
http://breast-cancer-research.com/content/13/3/R67
Page 3 of 9Table 2 Treatment administered
Treatment Age (years) Overall CTC < 5 CTC ≥ 5
Endocrine treatment 56 (36 to 82) 47 (20.0) 33 (70.2) 14 (29.8)
Aromatase inhibitor 35 (74.5) 25 (71.4) 10 (28.6)
Tamoxifen 8 (17.0) 6 (75.0) 2 (25.0)
Fulvestrant 4 (8.5) 2 (50.0) 2 (50.0)
Monochemotherapy 57 (31 to 81) 45 (19.1) 23 (51.1) 22 (48.9)
Taxane 21 (46.7) 12 (57.1) 9 (42.9)
Other
a 24 (53.3) 11 (45.8) 13 (54.2)
Combination chemotherapy 53 (23 to 78) 64 (27.2) 40 (62.5) 24 (37.5)
Taxane + anthracycline 25 (39.1) 16 (64.0) 9 (36.0)
Taxane + capecitabine 22 (34.4) 13 (59.1) 9 (40.9)
Taxane + other cytotoxic agent
b 7 (10.9) 5 (71.4) 2 (28.6)
Other
c 10 (15.6) 6 (60.0) 4 (40.0)
Chemotherapy + anti-HER2 drugs 53 (28 to 81) 40 (17.0) 26 (65.0) 14 (35.0)
Chemotherapy + trastuzumab
d 30 (75.0) 17 (57) 13 (43)
Chemotherapy + lapatinib 10 (25.0) 9 (90) 1 (10)
Chemotherapy + bevacizumab 49 (30 to 67) 39 (16.6) 19 (48.7) 20 (51.3)
Monochemotherapy + bevacizumab 32 (82.1) 18 (56.2) 14 (43.8)
Polychemotherapy + bevacizumab 7 (17.9) 1 (14.3) 6 (85.7)
Data presented as n (%) or median (range). CTC, circulating tumor cell; HER-2, human epidermal growth factor receptor-2.
aCapecitabine (n = 17), epirubicin (n =
1), vinorelbine (n = 1), gemcitabine (n = 3), carboplatin (n = 2).
bTaxane + carboplatin (n = 6), taxane + gemcitabine (n = 1).
c5-Fluorouracil + epirubicin +
cyclophosphamid (n = 5), fluorouracil + doxorubicin + cyclophosphamid (n = 2), gemcitabine + carboplatin (n = 3).
dTaxane-based chemotherapy + trastuzumab
(n = 24).
(a)
Progression-Free Survival (months)
CTCs <5  n=141
CTCs 5  n=94
(b)
P
r
o
b
a
b
i
l
i
t
y
Months
P
r
o
b
a
b
i
l
i
t
y
Months
CTC <5 12.0
7.0
9.6 to 14.3
5.8 to 8.2
< 0.001
CTC 5
Group Median 95% C.I. Log-rank P
CTC <5 40.1
21.9
34.9 to 45.4
15.6 to 28.4
< 0.001
CTC 5
Group Median 95% C.I. Log-rank P
Overall Survival (months)
CTCs <5  n=141
CTCs 5  n=94
Figure 1 Prognostic value of circulating tumor cells in the overall population.E s t i m a t e d(a) progression-free survival and (b) overall
survival according to baseline circulating tumor cell (CTC) value (< 5 vs. ≥ 5) in the overall population. C.I., confidence interval.
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mab and chemotherapy plus HER-2-targeting drugs in
patients with a high baseline CTC count was consider-
able, with a reduction of CTC number to below the
threshold of 5 in 16 out of 17 (94%) and in nine out of
nine (100%) subjects, respectively. Instead, chemother-
apy or endocrine therapy were associated with a CTC
reduction in 16 out of 40 cases (40%). Specifically, endo-
c r i n et r e a t m e n tw a sa b l et or e d u c eC T C su n d e rt h e
threshold of 5 only in one out of 10 (10%) patients -
whereas chemotherapy alone had a more pronounced
effect, inducing a reduction of CTCs to < 5 in 15 out of
30 cases (50%).
Prognostic value of circulating tumor cells according to
different first-line treatments
The differential ability of each modality of treatment to
reduce the CTC number led us to evaluate whether the
most effective therapies could impact the negative prog-
nostic value associated with a high count of CTCs. We
evaluated the CTC prognostic value in all treatment
groups, including endocrine therapy, chemotherapy
alone, chemotherapy plus bevacizumab, and chemother-
apy plus HER-2-targeting drugs (Figure 2).
CTCs remained a strong prognostic indicator in
patients receiving endocrine treatment or chemotherapy
alone. In both of these treatment groups, a high CTC
count was associated with poor outcome, particularly in
patients receiving endocrine therapy (median PFS 14.1
vs. 3.5 months for subjects with CTC < 5 and ≥ 5,
respectively; log-rank P = 0.001; Figure 2). Even when
considering only the most effective chemotherapy regi-
mens, including either a taxane as a single agent or in
combination with other chemotherapeutic agents (that
is, anthracyclines, capecitabine, gemcitabine, carbopla-
tin), chemotherapy administered without any biologically
targeted agent did not impact the negative prognostic
value of CTCs (median PFS 12.6 months for patients
with CTCs < 5 and 7.1 for those with CTCs ≥ 5, P =
0.03). Conversely, in patients with HER-2-overex-
pressed/amplified disease treated with an anti-HER-2-
based treatment (trastuzumab n = 30, lapatinib n =1 0 ) ,
the prognostic value of CTCs was no longer sustainable
as subjects with baseline CTCs ≥ 5 received a dramatic
survival benefit from this therapy (median PFS 16.1
months, 95% CI = 4.1 to 28.1 months; Figure 2).
Furthermore, in women receiving taxane-based che-
motherapy plus bevacizumab, CTCs < 5 were associated
with neither a statistically significantly longer PFS nor
OS in comparison with CTCs ≥ 5 (median PFS 9.6
months and 7.3 months for patients with CTCs < 5 and
≥ 5, respectively, P = 0.481; Figure 2), suggesting a ther-
apeutic benefit confined to the worse prognostic group.
Predictive value of circulating tumor cells
Of the 148 patients with HER-2 normal disease who were
treated with chemotherapy, 64 (43.2%) received combina-
tion chemotherapy, 45 (30.4%) received single-agent che-
motherapy, and 39 (26.4%) were treated with
chemotherapy plus bevacizumab (Table 2). Those treat-
ments were selected according to patient characteristics
(such as age, co-morbidity) and to the traditional predic-
tive markers in use at the time of therapy administration.
We sought to explore a hypothetical predictive value
for CTCs, comparing different treatments (combination
chemotherapy versus monochemotherapy, and mono-
chemotherapy plus bevacizumab vs. monochemotherapy
alone) in patients with low (< 5) or high (≥ 5) baseline
CTC counts. Combination chemotherapy was superior
to single-agent chemotherapy, in terms of PFS, in both
CTC groups, although the benefit provided by combina-
tion regimens was primarily confined to patients with
CTCs ≥ 5 (test for heterogeneity P = 0.01; Figure 3).
With respect to OS, combination chemotherapy was
superior to monochemotherapy only in patients with
CTCs ≥ 5, but the heterogeneity between the two sub-
groups was not statistically significant (test for heteroge-
neity P = 0.16; Figure 3). Furthermore, the association
of chemotherapy with bevacizumab was superior to
monochemotherapy, regarding PFS, but only in patients
with a high baseline CTC count (hazard ratio = 0.88,
95% CI = 0.42 to 1.83 in patients with CTCs < 5; and
hazard ratio = 0.28, 95% CI = 0.12 to 0.64, in those with
CTCs ≥ 5; test for heterogeneity P = 0.04; Figure 3).
Table 3 Multivariable Cox proportional hazards model
Variable Progression-free survival Overall survival
Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
HR
+ vs. HR
- 0.63 (0.46 to 0.86) 0.003 0.51 (0.34 to 0.79) 0.002
HER-2 amplified/overexpressed vs. HER-2 normal 0.52 (0.34 to 0.79) 0.002 0.39 (0.21 to 0.73) 0.003
Visceral vs. other metastases 1.39 (0.92 to 2.05) 0.095 1.77 (0.95 to 3.30) 0.074
Number of metastatic sites (1 vs. 3 vs. ≥ 3) 0.88 (0.70 to 1.10) 0.266 0.67 (0.47 to 0.95) 0.024
Circulating tumor cells (< 5 versus ≥ 5) 0.58 (0.43 to 0.79) < 0.001 0.40 (0.26 to 0.62) < 0.001
CI, confidence interval; HER-2, human epidermal growth factor receptor-2; HR
+, estrogen receptor-positive and/or progesterone receptor-positive; HR
-, both
estrogen receptor-positive and progesterone receptor-negative.
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Our analysis confirms that CTCs are a clinically valuable
and independent prognostic marker in newly-diagnosed
MBC patients. Indeed, in the overall population, baseline
counts of CTCs were able to discriminate between two
groups of patients with different outcome, independently
of traditional prognostic factors (hormone receptor,
HER-2, or spread of metastatic disease). Moreover, our
data showed that the various first-line treatment modal-
ities may have differing capabilities in reducing the
number of CTCs. Based on these results, we hypothe-
sized that each treatment can provide a different survi-
val benefit in patients with a high baseline CTC count.
Our data demonstrated that women with high baseline
CTC counts received very little survival benefit from
first-line endocrine treatment, even if they were appro-
priate candidates for this therapy based on the hormone
receptor status of their primary or metastatic tumor.
Despite the limited statistical power of this analysis, our
findings suggest that endocrine therapy might be inade-
quate as first-line treatment for MBC patients with a
high number of CTCs and alternative approaches should
be prospectively tested for this population. Moreover, in
patients receiving chemotherapy alone, high baseline
CTC counts identified subjects who received a small
benefit from systemic treatment and would undoubtedly
be destined to early progression of disease and shorter
overall survival.
Interestingly, we found a lack of prognostic significance
of baseline CTC counts in patients receiving chemother-
apy along with targeted treatments. HER-2-targeting drugs
combined with chemotherapy reduced the number of
CTCs in all patients with a high baseline CTC count. Our
findings confirm previous preclinical and clinical studies
demonstrating a selective action of trastuzumab against
CTCs [21-23]. The ability of trastuzumab to target CTCs,
probably acting through antibody-dependent cell-
mediated cytotoxicity, could explain the high survival rates
exhibited in our study by patients with HER-2-positive dis-
ease, who had baseline CTCs ≥ 5. In a recent study, how-
ever, Riethdorf and colleagues showed that neoadjuvant
trastuzumab-based treatment, in a cohort of patients with
HER-2-positive early and locally advanced breast cancer,
had a limited effect on the number of HER-2-overexpres-
sing CTCs [14]. On the contrary, it was recently shown
that trastuzumab is capable of reducing CTC-expressing
Progression-Free Survival (months)
Overall Survival (months)
P
r
o
b
a
b
i
l
i
t
y
Months
(a)
(e)
P
r
o
b
a
b
i
l
i
t
y
Months
(f)
P
r
o
b
a
b
i
l
i
t
y
Months
P
r
o
b
a
b
i
l
i
t
y
Months
(b)
(g)
P
r
o
b
a
b
i
l
i
t
y
Months
P
r
o
b
a
b
i
l
i
t
y
Months
(c)
(h)
P
r
o
b
a
b
i
l
i
t
y
Months
P
r
o
b
a
b
i
l
i
t
y
Months
(d) Endocrine therapy Chemotherapy alone Chemotherapy + 
bevacizumab
Chemotherapy + HER-2 
targeting drugs
CTC <5 14.1
3.5
9.2 to 19.1
0 to 11.9
0.001
CTC 5
Group Median 95% C.I. Log-rank P
CTC <5   n=33
CTC 5   n=14
Progression-Free Survival (months)
CTC <5 11.5
6.0
7.6 to 15.3
5.1 to 6.8
0.003
CTC 5
Group Median 95% C.I. Log-rank P
CTC <5    n=63
CTC 5    n=46
Progression-Free Survival (months)
CTC <5 9.6
7.3
4.6 to 14.7
5.5 to 9.2
0.481
CTC 5
Group Median 95% C.I. Log-rank P
CTC <5 N.R.
17.3
---
4.2 to 30.4
0.012
CTC 5
Group Median 95% C.I. Log-rank P
Overall Survival (months)
CTC <5 36.3
17.1
23.9 to 48.7
12.4 to 21.8
<0.001
CTC 5
Group Median 95% C.I. Log-rank P
Overall Survival (months)
CTC <5 N.R.
23.1
---
7.2 to 39.0
0.304
CTC 5
Group Median 95% C.I. Log-rank P
Progression-Free Survival (months)
CTC <5 14.5
16.1
8.3 to 20.8
4.1 to 28.1
0.947
CTC 5
Group Median 95% C.I. Log-rank P
Overall Survival (months)
CTC <5 N.R.
N.R.
---
---
0.919
CTC 5
Group Median 95% C.I. Log-rank P
CTC <5    n=19
CTC 5    n=20
CTC <5    n=26
CTC 5    n=14
CTC <5   n=33
CTC 5   n=14
CTC <5   n=63
CTC 5   n=46
CTC <5   n=19
CTC 5   n=20
CTC <5   n=26
CTC 5   n=14
Figure 2 Prognostic value of circulating tumor cells according with different first-line treatments. Estimated progression-free survival and
overall survival according to baseline circulating tumor cell (CTC) value (< 5 vs. ≥ 5) in patients receiving (a), (e) endocrine therapy, (b), (f)
chemotherapy alone, (c), (g) chemotherapy + bevacizumab, and (d), (h) chemotherapy + human epidermal growth factor receptor-2 (HER-2)-
targeting drugs. C.I., confidence interval.
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gesting another potential therapeutic use for this agent
[24]. There are currently no reports on the effect of lapati-
nib on CTCs, and future in-depth studies should evaluate
the potentially differential effect of the HER-2-targeted
therapies on CTCs.
Interestingly, bevacizumab administered in combination
with taxane-based chemotherapy reduced the number of
CTCs in almost all patients who began therapy with a
high count. This reduction did not, however, translate into
a striking survival benefit. Indeed, among women receiving
bevacizumab, there was still a trend in survival favoring
patients with CTCs < 5, although the difference was not
statistically significant. This result is consistent with pre-
viously published data showing an unclear prognostic
impact of CTCs in patients receiving bevacizumab. Bidard
and colleagues have shown that baseline CTCs predicted
worse time to progression in 67 breast cancer patients
receiving bevacizumab-based therapy, only using a cut-off
point of three CTCs, with no clinical significance asso-
ciated with the traditional threshold [25]. A recently pub-
lished meta-analysis of 43 randomized trials, comparing
combination chemotherapy versus single-agent che-
motherapy regimens, showed a statistically significant
advantage in terms of survival, tumor response and time
to progression for polychemotherapy, although it caused
more toxicity [26]. An alternative to polychemotherapy for
HER-2-negative patients has been provided by the associa-
tion of bevacizumab with chemotherapy. Several rando-
mized trials - including E2100, AVADO, RIBBON-1 and
RIBBON-2 - have demonstrated that bevacizumab-based
combination therapies, compared with chemotherapy
alone, improved the response rate and PFS, although no
study showed an improvement in OS [27-30]. Further-
more, to date there are no biomarkers that can predict
which patients may obtain most benefit from bevacizu-
mab. Our study identified a group of patients of worse
prognosis who benefited greatly from more aggressive
Figure 3 Predictive value of circulating tumor cells. Comparison of different first-line treatments according to circulating tumor cell (CTC)
baseline value. (a) Combination chemotherapy (poly-CTx) versus single-agent chemotherapy (mono-CTx). (b) Monochemotherapy +
bevacizumab (CTx + bev.) versus single-agent chemotherapy (mono-CTx). CI, confidence interval; IV, inverse variance; SE, standard error.
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monochemotherapy plus bevacizumab (both compared
with single-agent chemotherapy). The main limitations of
our analysis are the lack of randomized comparisons,
which implies potential confounding factors, and the lim-
ited number of patients. Nevertheless, to our knowledge,
this is the first study exploring the role of CTCs as a pre-
dictive marker in untreated MBC patients. We believe that
our novel findings can serve as a hypothesis generator,
supporting the utility to test CTCs as a predictive tool in
larger randomized trials.
Conclusions
In conclusion, our data confirm the prognostic value of
CTC enumeration and provide evidence that CTCs can
be studied as a unique model to develop tailored treat-
ments for MBC patients.
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